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eply
antinotti et al. (1) propose adopting the 97.5th percentile value as
cutoff for B-type natriuretic peptide (BNP) levels based on the
esults of their excellent study in presumed healthy newborns.
sing cutoff values based on the distribution from a healthy
opulation is fundamentally different from the derivation of cutoffs
rom a study of disease and nondisease subjects. The Better Not
out Children! Study (2) was a field test of sick infants and
hildren whose presentation could be caused by cardiovascular
isease. The results are intended to be applied to similar patients
n clinical practice. In the presence of trial data, use of 97.5th-
ercentile cutoffs fails to take advantage of valuable information
rom individuals who suffer from the disease but have test values
hat fall within 2 SDs above the mean of healthy subjects. For
xample, with the cutoffs proposed by Cantinotti et al. (1), the
ensitivity was only 43% and 49% for the 0- to 2-day-old and 3- to
-day-old groups, respectively, and 100% specific for both groups
f subjects from our study. Thus, the result of using this method-
logy, choosing the 97.5th percentile cutoff and applying it to a
ifferent group of subjects, would have increased test specificity
nd sacrificed sensitivity. We found in our study that, between
irth and 7 days of age, a cutoff of 170 pg/ml was sufficient to
iagnose significant cardiovascular disease with excellent sensitivity
93%) and reasonable specificity (73%). We believe that optimi-
ation of the sensitivity is clinically important in the identification
3f significant cardiovascular disease in the sick infant by the
rontline physician.
A second point relates to the dramatic fall in BNP values during
he first week of life. Multiple works (1,3) have shown that BNP
alues decrease dramatically in the first week of life and vary widely
ithin each age group even when separated by a single day. Thus,
t would be preferable to determine daily cutoffs during this critical
nd rapidly changing early phase of life. Unfortunately, our study
as neither intended nor powered to address this important
uestion.
Properly conducted prospective trials in pediatric cardiology are
acking. Instead of extrapolating data from normative values,
etrospective studies, or adult trials, prospective trials in children
hould be conducted. Ours was one of the early trials and hopefully
ot the last to assess BNP in children. Future studies should
ddress: 1) neonatal cutoffs by expanding the pool and sample size
f sick neonates; and 2) whether using BNP actually enhances the
iagnostic process and the outcome of the patient. There is much
romise in the use of BNP to diagnose significant cardiovascular
isease in children. But because of the tremendous physiological
nd disease heterogeneity in children, that test cutoff is truly a
oving target, and much work still has to be done.
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